Lantern Pharma Statistics

Total Valuation

Lantern Pharma has a market cap or net worth of $46.70 million. The enterprise value is $18.94 million.

Market Cap	46.70M
Enterprise Value	18.94M

Important Dates

The next estimated earnings date is Monday, March 17, 2025, after market close.

Earnings Date	Mar 17, 2025
Ex-Dividend Date	n/a

Share Statistics

Lantern Pharma has 10.78 million shares outstanding. The number of shares has decreased by -0.84% in one year.

Current Share Class	10.78M
Shares Outstanding	10.78M
Shares Change (YoY)	-0.84%
Shares Change (QoQ)	+0.04%
Owned by Insiders (%)	0.39%
Owned by Institutions (%)	23.34%
Float	7.96M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.76
P/TBV Ratio	1.76
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 8.31, with a Debt / Equity ratio of 0.01.

Current Ratio	8.31
Quick Ratio	7.79
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -53.03% and return on invested capital (ROIC) is -36.51%.

Return on Equity (ROE)	-53.03%
Return on Assets (ROA)	-33.94%
Return on Invested Capital (ROIC)	-36.51%
Return on Capital Employed (ROCE)	-79.41%
Revenue Per Employee	n/a
Profits Per Employee	-$909,140
Employee Count	21
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +8.52% in the last 52 weeks. The beta is 1.60, so Lantern Pharma's price volatility has been higher than the market average.

Beta (5Y)	1.60
52-Week Price Change	+8.52%
50-Day Moving Average	4.11
200-Day Moving Average	4.25
Relative Strength Index (RSI)	46.51
Average Volume (20 Days)	169,896

Short Selling Information

The latest short interest is 238,666, so 2.21% of the outstanding shares have been sold short.

Short Interest	238,666
Short Previous Month	187,398
Short % of Shares Out	2.21%
Short % of Float	3.00%
Short Ratio (days to cover)	1.53

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-21.20M
Pretax Income	-17.75M
Net Income	-19.09M
EBITDA	-21.18M
EBIT	-21.20M
Earnings Per Share (EPS)	-$1.77

Full Income Statement

Balance Sheet

The company has $28.05 million in cash and $291,244 in debt, giving a net cash position of $27.76 million or $2.57 per share.

Cash & Cash Equivalents	28.05M
Total Debt	291,244
Net Cash	27.76M
Net Cash Per Share	$2.57
Equity (Book Value)	26.60M
Book Value Per Share	2.47
Working Capital	26.32M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$17.23 million and capital expenditures -$14,593, giving a free cash flow of -$17.24 million.

Operating Cash Flow	-17.23M
Capital Expenditures	-14,593
Free Cash Flow	-17.24M
FCF Per Share	-$1.60

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Lantern Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.84%
Shareholder Yield	0.84%
Earnings Yield	-40.88%
FCF Yield	-36.92%

Analyst Forecast

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	Hold
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1